Abstract
Background: The presence of skin involvement has been accepted as a relative contraindication to breast preservation because it is believed to be associated with an increased local failure rate. This study was conducted to assess the outcome of a carefully selected group of patients who presented with breast cancer involving the skin and who had breast conservation therapy (BCT) following neoadjuvant chemotherapy.
Methods: Between 1987 and 1999, 33 patients with stage IIIB or IIIC breast cancer completed treatment consisting of four cycles of neoadjuvant chemotherapy, lumpectomy, radiation therapy, and consolidative chemotherapy. Clinicopathologic factors were analyzed and patients were followed for locoregional and distant recurrence.
Results: Initial median tumor size was 7 cm. All patients had skin involvement, defined as erythema, skin edema, direct skin invasion, ulceration, or peau d’orange. Following chemotherapy, median pathologic tumor size was 2 cm. Complete resolution of skin changes occurred in 29 patients (88%). At median follow-up time of 91 months in surviving patients, 26 patients (79%) were alive without evidence of disease. The 5-year, disease-free survival rate was 70%, and the 5-year overall survival rate was 78%. The actuarial ipsilateral breast cancer recurrence rate was 6% at 5 years.
Conclusions: Patients who present with T4 breast cancer who experience tumor shrinkage and resolution of skin changes with neoadjuvant chemotherapy represent a select group of patients who can have BCT. These patients have favorable rates of long-term local control and survival. Mastectomy is not mandatory for all patients with breast cancer who present with skin involvement.
Similar content being viewed by others
REFERENCES
Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1997;74:416–23.
Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced noninflammatory breast cancer. Surg Clin North Am 1996;76:196–207.
Hunt KK, Buzdar AU. Breast conservation after tumor downstaging with induction chemotherapy. In: Singletary S, eds. Breast Cancer New York: Springer-Verlag, 1998;196–205
Singletary SE. Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer. Am J Surg 2001;182:341–6.
Kuerer HM, Hunt KK, Newman LA, Ross MI, Ames FC, Singletary SE. Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. J Am Coll Surg 2000;190:350–63.
Hortobagyi GN, Singletary SE, McNeese MD. Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast Philadelphia: Lippincott-Raven, 585–99
Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763–8.
Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62:2507–16.
Green M, Hortobagyi GN. Neoadjuvant chemotherapy for operable breast cancer. Oncology 2002;16:871–98.
Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990;66:119–29.
Calais G, Berger C, Descamps P, et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 1994;74:1283–8.
Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomized trial: S6. Eur J Cancer 1994;30A:645–52.
Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995;222:612–8.
Touboul E, Lefranc JP, Blondon J, et al. Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. Radiother Oncol 1997;42:219–29.
Merajver SD, Weber BL, Cody R, et al. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol 1997;15:2873–81.
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operative breast cancer. J Clin Oncol 1998;16:2672–85.
Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93–100.
Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179–84.
Clark J, Rosenman J, Cance W, Halle J, Graham M. Extending the indications for breast-conserving treatment to patients with locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1998;42:345–50.
Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Ann Oncol 1999;10:47–52.
Kuerer HM, Singletary SE, Buzdar AU, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 2001;182:601–8.
Favret AM, Carlson RW, Goffinet DR, Jeffrey SS, Dirbas FM, Stockdale FE. Locally advanced breast cancer: is surgery necessary?. Breast J 2001;7:131–7.
Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002;236:295–303.
Inaji H, Komoike Y, Motomura K, et al. Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer. Breast Cancer 2002;9:20–5.
McIntosh SA, Ogston KN, Payne S, et al. Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 2003;185:525–31.
Chen AM, Meric F, Hunt KK, et al. Breast-conserving therapy after neoadjuvant chemotherapy: the M. D. Anderson Cancer Center experience [abstract]. 26th Annual San Antonio Breast Cancer Symposium, December 3–6, 2003.
Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992;69:2849–52.
Booser D, Frye D, Singletary SE, Hortobagyi GN. Response to induction chemotherapy for breast cancer: a prospective multimodality treatment program [abstract]. Proc Am Soc Clin Oncol 1992;11:82.
Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003;83:803–19.
Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998;176:502–9.
Machiavella MR, Romero AO, Perez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125–31.
Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460–9.
Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002;80:4–11.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shen, J., Valero, V., Buchholz, T.A. et al. Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy. Ann Surg Oncol 11, 854–860 (2004). https://doi.org/10.1245/ASO.2004.02.003
Issue Date:
DOI: https://doi.org/10.1245/ASO.2004.02.003